The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 701–800 of 849
Defining resectability of colorectal liver metastases: how and why?
van Voorthuizen, T., van Gulik, T. M., & Punt, C. J. A. (2013) · Colorectal Cancer · doi:10.2217/crc.12.79 · Cited by 1
Siegelmann‐Danieli, N., Farkash, A., Katzir, I., Vesterman‐Landes, J., Rabinovich, H. R., Lomnicky, Y., Carmeli, B., & Parush, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154689 · Cited by 1
Irinotecan therapy—following a trail of breadcrumbs?
Goldberg, R. M., & O’Neil, B. H. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.140 · Cited by 1
Takahashi, N., Iwasa, S., Fukahori, M., Sudo, K., Sasaki, Y., Shoji, H., Honma, Y., Okita, N. T., Takashima, A., Hamaguchi, T., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3111-x · Cited by 1
Izar, B., Ryan, D. P., & Chabner, B. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00009-5 · Cited by 1
Combination of Anti-angiogenics and Other Targeted Therapies
Zirlik, K., & Duyster, J. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_14 · Cited by 1
Giuliani, J., & Bonetti, A. V. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1347504 · Cited by 1
Metastatic malignant liver tumors
Winter, J., & Auer, R. C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00081-3 · Cited by 1
Imiter la réponse immunitaire humorale polyclonale
Larbouret, C., Poul, M., & Chardès, T. (2019) · médecine/sciences · doi:10.1051/medsci/2019216 · Cited by 1
Targeted Therapies for Colorectal Cancer
Russo, A., Galvano, A., Bronte, G., & Peeters, M. (2015) · Current clinical pathology · doi:10.1007/978-1-4939-2047-1_13 · Cited by 1
Saeki, H., Komeda, T., Tanaka, R., Yamatani, Y., & Sakai, H. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00392-2 · Cited by 1
Combination of Antiangiogenics and Other Targeted Therapies
Zirlik, K., & Duyster, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_14-1 · Cited by 1
Bekaii‐Saab, T., Balser, S., Lohmann, R., Daoud, H., Liedert, B., & Schliephake, D. E. (2022) · Colorectal Cancer · doi:10.2217/crc-2022-0002 · Cited by 1
Monoclonal Antibodies in Cancer Therapy
-, T. I., -, P. C., & -, K. R. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i05.6242 · Cited by 1
Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis
Saowapa, S., Polpichai, N., Siladech, P., Wannaphut, C., Tanariyakul, M., Wattanachayakul, P., Bernal, D. A. O., Pleitez, H. J. G., & Tijani, L. (2024) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2024.2342723 · Cited by 1
Novel Anti-angiogenic Therapies in Ovarian Cancer
Hasan, J., & Jayson, G. C. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7216-3_3 · Cited by 1
Thérapeutiques ciblées dans le traitement des tumeurs solides
Beuzeboc, P. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0021-9_5 · Cited by 1
Systemic Therapy for Patients with Colorectal Cancer: State of the Art
Pfeiffer, P., Qvortrup, C., & Tabernero, J. M. (2014) · Springer eBooks · doi:10.1007/978-3-319-06142-9_13 · Cited by 1
Therapie des metastasierten Kolonkarzinoms
Folprecht, G., Bokemeyer, C., & Weitz, J. (2009) · Der Onkologe · doi:10.1007/s00761-009-1723-z · Cited by 1
Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS
Saltz, L. B. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0134-5 · Cited by 1
Qvortrup, C., & Pfeiffer, P. (2015) · University of Southern Denmark Research Portal (University of Southern Denmark) · doi:10.3978/j.issn.2224-4778.2014.08.12 · Cited by 1
Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer
Monzon, J. G., & Dancey, J. E. (2020) · doi:10.1201/9781003159469-7 · Cited by 1
Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer
Çiftçi, R., & Tural, D. G. (2016) · InTech eBooks · doi:10.5772/62304 · Cited by 1
Arvide, E. M., & Velasco, J. D. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.7.10 · Cited by 1
Drugs that act on the immune system
Spoerl, D., & Bircher, A. J. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00037-4 · Cited by 1
Therapeutic Drug Monitoring of Selected Anticancer Drugs
Milone, M. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385467-4.00014-2 · Cited by 2
Conventıonal and targeted therapy in metastatıc colorectal cancer
Sedef, A. M., & Sümbül, A. T. (2018) · Journal of Cancer Prevention & Current Research · doi:10.15406/jcpcr.2018.09.00369 · Cited by 1
Rodríguez, C. A., Abal, M., Alconada, L. A., Folgar, S. C., López‐López, R., & Saborido, C. M. (2019) · Global & Regional Health Technology Assessment · doi:10.1177/2284240319858331 · Cited by 1
The Role of Liver Transplantation for Liver Metastasis from Colorectal Cancer
Tomiyama, K., Dokus, M. K., Errigo, J., Laryea, M. A., & Hernandez‐Alejandro, R. (2020) · Digestive Disease Interventions · doi:10.1055/s-0040-1705094 · Cited by 1
Minsky, B. D., Rödel, C. M., & Valentini, V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00049-3 · Cited by 1
Czito, B. G., Hsu, D. S., Palta, M., & Willett, C. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00050-2 · Cited by 1
Panitumumab Therapy and RAS and BRAF Genotype
Dean, L., & Kane, M. S. (2012) · Cited by 1
Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer
Monzon, J. G., & Dancey, J. E. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-8 · Cited by 1
Rodríguez, C. A., Abal, M., Alconada, L. A., Folgar, S. C., López‐López, R., & Saborido, C. M. (2019) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2019.459 · Cited by 1
Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer
Kügler, J. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch66 · Cited by 1
When More is Worse in Clinical Research and Clinical Practice
Tassinari, D., Tombesi, P., & Sartori, S. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181b0c359 · Cited by 1
Bevacizumab in the management of colorectal cancer: A review
Ang, C., & Kemeny, N. E. (2011) · Journal of Solid Tumors · doi:10.5430/jst.v1n3p120 · Cited by 1
Reply to Dr. Kabbinavar and Dr. Kozloff
Stathopoulos, G. P. (2011) · Oncology · doi:10.1159/000327226 · Cited by 1
Recent advances in treatment of metastatic colorectal cancer
Haraldsdóttir, S., & Goldberg, R. M. (2012) · Clinical Investigation · doi:10.4155/cli.12.116 · Cited by 1
Chemotherapy Trials for Colorectal Cancer in Advanced Disease: What’s the Current Hypothesis?
Nikapota, A. D., Harrison, M., & Glynne‐Jones, R. (2009) · Springer eBooks · doi:10.1007/978-1-84882-756-1_4 · Cited by 1
Kamrava, M. R., Rixe, O., & Gulley, J. L. (2009) · Therapy · doi:10.2217/thy.09.7 · Cited by 1
Adenocarcinoma of the Colon and Rectum
Weiser, M. R., Posner, M. C., & Saltz, L. B. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2206-2.00164-0 · Cited by 1
Bibliometric analysis on randomized controlled trials of colorectal cancer over the last decadePreprint
Hu, J., Wang, C., Zhou, S.-C., Li, X., Li, B., Zhang, J., Ge, Z., & Zhang, Q. (2020) · doi:10.21203/rs.2.23370/v1 · Cited by 1
Systemic Treatment in Recurrent and Metastatic Unresectable Rectal Cancer
Otte, F.-X., Tehfe, M. A., Ayoub, J.-P., & Aubi, F. (2011) · InTech eBooks · doi:10.5772/27449
Anti-EGFR Treatment in Patients with Colorectal Cancer
Qvortrup, C., & Pfeiffer, P. (2012) · InTech eBooks · doi:10.5772/30080
Hepatic Tumors: An Oncologist's Perspective
Weatherstone, K., Childs, A., & Meyer, T. (2013) · Wiley eBooks · doi:10.1002/9781118555651.ch25
Analyses of Akt and PDGF receptor expression and activation in human tumors
Paulsson, J. (2009) · Figshare
Maekawa, H., Orita, H., Sakurada, M., Kushida, T., Ito, T., & Sato, K. (2015) · International Journal of Case Reports and Images · doi:10.5348/ijcri-201585-cr-10546
Franco, S. D., Benfante, A., Iovino, F., Bonventre, S., Dieli, F., Stassi, G., & Todaro, M. (2012) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201100021 · Cited by 1
Targeting treatment for colorectal cancer: The EGFR antibody story
Chin, M. T. M., & Ward, R. L. (2014) · Cancer Forum
Cancer colorectal: stratégies thérapeutiques en situation métastatique
Senellart, H., Hiret, S., & Bennouna, J. (2010) · ONCOLOGIE · doi:10.1007/s10269-010-1950-3
Zhuang, G., & Ferrara, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_18
Molecular Markers of Chemotherapy Response in Colorectal Cancer
Braun, M. S., & Seymour, M. (2010) · Current Colorectal Cancer Reports · doi:10.1007/s11888-010-0052-3
First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery
Murad, A. M., & Murad, L. S. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0259-4
Giuliani, J., Mercanti, A., Muraro, S., Trolese, A. R., Durante, E., Greco, F., Piacentini, P., Tognetto, M., & Bonetti, A. V. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.982099
The importance of KRAS status in managing metastatic colorectal cancer
Leong, S., Eckhardt, S., Jimeno, A., & Messersmith, W. A. (2009) · Current Colorectal Cancer Reports · doi:10.1007/s11888-009-0019-4
Optimizing first-line chemotherapy for metastatic colorectal cancer
Adams, R. (2012) · Colorectal Cancer · doi:10.2217/crc.12.21
Optimal integration of EGFR inhibitors in advanced colorectal cancer
Nelson, D. A., & Jasani, N. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70066-9
RAS mutations: impact on treatment outcome
Mikhail, S., & Bekaii‐Saab, T. (2013) · Colorectal Cancer · doi:10.2217/crc.13.63
Colon Cancer Liver Metastasis: Addition of Antiangiogenesis or EGFR Inhibitors to Chemotherapy
Cruz, M. R. S., & Lopes, G. D. L., Jr. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0148-z
Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials
García, M., Navarro, V., & Clopés-Estela, A. (2014) · Current Colorectal Cancer Reports · doi:10.1007/s11888-014-0227-4
Neue Entwicklungen in der Zytostatikatherapie
Kumpf, S., der Heinrich, U., & Düsseldorf, H.-U. (2009)
Optimum Duration of Metastatic Colorectal Cancer Treatment
Stein, A., & Schmoll, H. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0179-0
Thérapies ciblées dans le traitement des cancers colorectaux métastatiques : place actuelle
Cacheux, W., Tourneau, C. L., Baranger, B., Mignot, L., & Mariani, P. (2011) · Journal de Chirurgie Viscérale · doi:10.1016/j.jchirv.2010.12.007
Newer Agents in Colon Cancer: What’s Next?
Arango, B. A., & Akunyili, I. I. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0157-y
Promiscuous antibody targets cancer
Ledford, H. K. (2009) · Nature · doi:10.1038/news.2009.175
Grothey, A. A. (2009) · Current Colorectal Cancer Reports · doi:10.1007/s11888-009-0010-0
Troiani, T., Venturini, F., Napolitano, S., Martini, G., Gambardella, V., Ciardiello, F., & Martinelli, E. (2014) · Colorectal Cancer · doi:10.2217/crc.14.17
Agents antiangiogéniques et association de TMC: attention danger
Massard, C. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2143-z
Pushing an Old Issue Towards a New Front Line
Takiguchi, Y. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr100
Thymidylate synthase expression and mismatch repair protein expression in colorectal cancer
Öhrling, K. (2010) · Figshare
Ciombor, K. K., & Goldberg, R. M. (2014) · Hepatic Oncology · doi:10.2217/hep.14.13
Byström, P. (2010) · Figshare
Intensive screening for resected stage II and III colorectal cancer
Fakih, M. (2012) · Colorectal Cancer · doi:10.2217/crc.11.1
Targeted Therapies For Intestinal Tumorigenesis
Chiorean, E. G., Coveler, A. L., Grim, J. E., & Grady, W. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_13
Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways
Grépin, R., Guyot, M., & Pagès, G. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0466-8_20
Predictive oncology comes to colorectal cancer
Jonker, D. J., Cripps, C., & Goel, R. (2009)
Biomarkers Molecular biomarkers in colorectal cancer in pursuit of personalizing treatment
Lai, S. M., Oseran, A. S., & Marshall, J. L. (2014)
Self-citationEvidence-Based Medicine: What does it Mean and Where Are We Going?
Frustaci, S., Miolo, G., Buonadonna, A., Crivellari, D., & Scalone, S. (2010) · Springer eBooks · doi:10.1007/978-3-642-05025-1_14
The Clinical Significance of Mutations in Colorectal Cancer
Huang, F. W., Kleiman, L. B., & Hong, T. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8412-7_8
Ålgars, A. (2012) · UTUPub (University of Turku)
Looking ahead to rational combinatorial therapy
Mittra, A., & Tripathy, D. (2012) · Community Oncology · doi:10.1016/j.cmonc.2012.02.002
Cetuximab plus FOLFIRI as a first-line therapy in metastatic colorectal cancer
Haller, D. G. (2012) · Community Oncology · doi:10.1016/j.cmonc.2012.10.001
What is the Optimal Treatment for Metastatic Colorectal Cancer? Controversial Points
Cidón, E. U. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.s4-003
Anti-angiogenic agents in treatment of metastatic colo-rectal cancers
Lledo, G., de Gramont, A., & Saint-Antoine, H. (2010)
Gastrointestinal and Pancreatobiliary Tumors
Matin, K., & Gordon, S. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-16304-8_12
Mutational analysis of KRAS and NRAS in metastatic colorectal cancer
Silva, R. O. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/2b6q-gd76
Venook, A. P., Bendell, J. C., & Warren, R. S. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.50
Yasuda, H., Nakayama, K., Sasaki, T., & Yanagihara, K. (2009) · Immunotherapy · doi:10.2217/imt.09.18
Signal Transduction Inhibitors of the HER Family
Brzezniak, C. E., Carter, C. A., Thomas, A., & Giaccone, G. (2013) · CRC Press eBooks · doi:10.1201/b15944-3
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Lopez, N., & Yeh, J. J. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-34244-3_19
Métastases hépatiques de cancer colo-rectal : stratégie médico-chirurgicale
Malka, D., & Cunha, A. S. (2009) · La Lettre du cancérologue
Ducreux, M. P., Boige, V., Malka, D., & Burtin, P. C. (2009) · Springer eBooks · doi:10.1007/978-2-287-99247-6_7
Ongoing Adjuvant/Neoadjuvant Trials in Resectable Metastatic Colorectal Cancer
Krell, D., & Glynne‐Jones, R. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0342-5
Therapeutic Monoclonal Antibodies and Their Targets
Figueroa, J. A., Peña, C., Mirandola, L., Reidy, A., Payne, J. D., Hosiriluck, N., Suvorava, N., Rahman, R. L., Whitlow, A. R., Verma, R., et al. (2016) · doi:10.1002/9781118940648.ch4
Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer
Chibaudel, B., Tournigand, C., Larsen, A. K., & de Gramont, A. (2016) · Springer eBooks · doi:10.1007/978-94-017-7755-1_16
Translational Study of Liver Cancer and Hypertrophy: TranSLiCH
Abraham, T., & Enrique, M. (2016) · Scholarship@Western (Western University)
Farmacogenética en el tratamiento del cáncer colorrectal
López-Bravo, D. P. (2012) · TDX (Tesis Doctorals en Xarxa)
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
